---
title: "Novogene (688315): Won the procurement project of Shenzhen Bay Laboratory, with a bid amount of 5 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288879546.md"
description: "Novogene announced that it won the bid for the Shenzhen Bay Laboratory \"Human Genome Resequencing Analysis Project,\" with a bid amount of 5 million yuan. The company mainly focuses on library construction sequencing and research services, with revenue of 2.21 billion yuan in 2025 and revenue of 556 million yuan in the first quarter of 2026"
datetime: "2026-06-05T14:40:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288879546.md)
  - [en](https://longbridge.com/en/news/288879546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288879546.md)
generator: "portal-rs"
---

# Novogene (688315): Won the procurement project of Shenzhen Bay Laboratory, with a bid amount of 5 million yuan

According to Tongbi Finance, data from Qichacha shows that based on the announcement of the bidding results for the "Human Genome Resequencing Analysis Project (Reprocurement for the First Time)", Beijing Novogene Technology Co., Ltd. announced on June 5, 2026, that it won the procurement project of Shenzhen Bay Laboratory, with a winning amount of 5 million yuan.

Related listed company: Novogene (688315.SH)

*Tongbi Finance Tip:*

*Novogene (688315.SH) had an operating income of 2.21 billion yuan in 2025, with a growth rate of 4.66%. The net profit attributable to the parent company was 167 million yuan, with a growth rate of -15.16%. The return on net assets was 6.49%.*

*In the first quarter of 2026, the company's operating income was 556 million yuan, with a growth rate of 10.84%. The net profit attributable to the parent company was 29 million yuan, with a growth rate of -13.06%.*

*The company currently belongs to the healthcare industry, with main product types including servers and workstations, and professional consulting services. The 2025 report showed that the main business composition was library construction sequencing platform services: 48.08%; basic scientific research services in life sciences: 35.84%; medical research and technology services: 13.09%; others: 2.67%; other businesses: 0.33%.*

### Related Stocks

- [688315.CN](https://longbridge.com/en/quote/688315.CN.md)

## Related News & Research

- [10:38 ETStrengthen Total AAV Potency Assurance with NGS Sequence Analysis, Upcoming Webinar Hosted by Xtalks](https://longbridge.com/en/news/297062713.md)
- [GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s | WGS Stock News](https://longbridge.com/en/news/296789873.md)
- [Energy & Environment Investment makes follow-on investment in elleThermo](https://longbridge.com/en/news/297026645.md)
- [MPC Container Ships ASA Non-GAAP EPS of $0.09, revenue of $116.9M beats by $12.37M](https://longbridge.com/en/news/297007548.md)
- [15:05 ETTracy Young, MSNA, MBA, CRNA, Named 2026-27 President of the American Association of Nurse Anesthesiology](https://longbridge.com/en/news/296948606.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**